Table 3 Number (%) of adverse events and serious adverse in artemether-lumefantrine-treated subjects
Adverse events up to day 7 | Serious adverse events up to day 30 | |||
|---|---|---|---|---|
AL-treated asymptomatic carriers | AL-treated with symptomatic malaria episode with >5,000/μL parasites | AL-treated asymptomatic carriers | AL-treated with symptomatic malaria episode with >5,000/μL parasites | |
(n = 3,819) | (n = 2,554) | (n = 3,819) | (n = 2,554) | |
Abdominal pain | 1 (0.03%) | - | 1 (0.03%) | - |
Nausea | 1 (0.03%) | - | 1 (0.03%) | - |
Vomiting | 1 (0.03%) | 14 (0.5%) | - | 21 (0.8%) |
Death | 1 (0.03%) | - | 1 (0.03%) | - |
Pyrexia | 1 (0.03%) | - | 1 (0.03%) | - |
Malaria | 5 (0.1%) | 2 (0.08%) | 4 (0.1%) | 5 (0.2%) |
Bronchitis | 2 (0.05%) | - | 2 (0.05%) | - |
Pneumonia | 2 (0.05%) | 1 (0.04%) | 2 (0.05%) | 2 (0.08%) |
Respiratory tract infection | 1 (0.03%) | - | 1 (0.03%) | - |
Dizziness | 1 (0.03%) | - | 1 (0.03%) | - |
Asthmatic crisis | 1 (0.03%) | - | - | - |
Somnolence | - | - | - | 1 (0.04%) |